Drug Trial Radar · NCT04516057
Nabilone for Agitation Blinded Intervention Trial
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Feb 1, 2021
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sunnybrook Health Sciences CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alzheimer's Drug Discovery Foundation
- First posted
- Aug 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events. Therefore, identifying safer and more effective treatments for agitation in AD is a clinical and research priority. Nabilone is a synthetic cannabinoid that is Health Canada-approved to treat chemotherapy-induced nausea and vomiting. The PI's research group completed a 6-week double-blind placebo-controlled randomized cross-over pilot trial in 38 patients with moderate-to-severe AD, providing the first preliminary evidence regarding the safety and efficacy of nabilone in this population. They found that nabilone significantly improved agitation, overall neuropsychiatric symptoms, and caregiver distress. That study was limited by its sample size and questions remain regarding the efficacy of nabilone for nutrition and pain and predictors of response. However, the promising preliminary findings encourage a pivotal, practice-changing phase III trial to inform clinical practice. Participants in this study will be randomized to receive either nabilone or a placebo for 8 weeks. In addition to looking at the effectiveness of nabilone in treating agitation, the researchers will also look at whether it is beneficial for other relevant outcomes for patients with AD including overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, and pain. Participants will also be followed for 8 weeks following completion of the study treatment.
Conditions
- Alzheimer Disease
- Agitation
Interventions
NabiloneDrug
After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
PlaceboOther
After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Agitation - Cohen-Mansfield Agitation Inventory (CMAI)Time frame: Baseline (0 Weeks) to 8 Weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada · Recruiting
Geras Centre for Aging Research, Hamilton Health Sciences
Hamilton, Ontario, Canada · Not yet recruiting
London Health Sciences Centre
London, Ontario, Canada · Recruiting
The University of Ottawa Institute of Mental Health Research at The Royal
Ottawa, Ontario, Canada · Not yet recruiting
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada · Recruiting
Centre for Addiction and Mental Health
Toronto, Ontario, Canada · Recruiting
St. Michael's Hospital
Toronto, Ontario, Canada · Terminated
Ontario Shores Centre for Mental Health Sciences
Whitby, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.